The new standard in medical weight loss: Discover how GLP-1 medications are rewriting the possibilities for sustainable, safe treatment of obesity.
GLP-1 (glucagon-like peptide-1) medications belong to a class of prescription drugs originally developed for type 2 diabetes. They work by mimicking a naturally occurring hormone that signals satiety (fullness) to the brain and slows digestion, ultimately reducing appetite and calorie intake.
But in the last few years, GLP-1 receptor agonists—such as semaglutide (Ozempic, Wegovy), liraglutide (Saxenda, Victoza), and tirzepatide (Mounjaro, Zepbound)—have been approved and widely adopted for weight management in patients with obesity or overweight and related conditions. These medications mark the most significant advance in prescription-based weight loss in over a decade.
Unlike older stimulant or appetite suppressant drugs, GLP-1s act on the body's own chemistry to produce real, lasting results.
GLP-1 medications act on multiple pathways that collectively make losing weight not just possible but sustainable:
These effects combine to lower daily calorie intake—without the jittery side effects of stimulants. As a result, patients on GLP-1 therapy typically experience a steady, significant reduction in body weight over time.
Interested in understanding alternative treatments? Review our detailed guides on weight loss drugs and weight loss medications for a wider overview.
| Medication | Avg. Weight Loss* | Notable Benefits | Typical Route |
|---|---|---|---|
| GLP-1s (Semaglutide, Liraglutide) | 10–15% | Appetite, glucose & heart health | Injection or oral |
| Bupropion/Naltrexone | 5–9% | Mood, cravings | Oral |
| Phentermine/Topiramate | 8–10% | Energy, appetite | Oral |
| Older anti-obesity drugs | 3–7% | Short-term use | Oral |
*Percent of starting weight lost after 1 year; always with diet, activity, and physician guidance.
Branded as Wegovy (for weight loss) and Ozempic (for diabetes), semaglutide is the first GLP-1 to demonstrate average 15% body weight loss in pivotal trials. Self-administered as a weekly injection, it's become the most referenced modern therapy for obesity.
Learn about semaglutideTirzepatide acts on both GLP-1 and GIP receptors, yielding the most dramatic weight loss—up to 22% in some trials. Approved for diabetes and obesity, it is currently prescribed for those who have not succeeded with other therapies.
See how tirzepatide worksThe first daily injectable GLP-1 approved for obesity, liraglutide produces 5–10% weight loss on average. It remains an important option for those requiring daily dosing or with contraindications to other GLP-1s.
About liraglutide